iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium

Loading news article.

iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium | WAPE

iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium

Article summary

Related companies

Comments —